OR WAIT null SECS
Anthony Qu, PhD, vice president of Scientific Affairs at Halo Pharma, will give a presentation on fixed-dose combination products, drug products containing multiple active ingredients, as an effective approach for simplified dosing at CPhI North America on Wednesday, April 25, 2018 in Philadelphia, PA.
On April 5, 2018, contract development and manufacturing organization, Halo Pharma, announced that Anthony Qu, PhD, vice president of Scientific Affairs, will present on fixed-dose combination products (FDCs), drug products containing multiple active ingredients, as an effective approach for simplified dosing at CPhI North America 2018 on Wednesday, April 25, 2018 in Philadelphia, PA.
The presentation will explore the challenges and solutions in the manufacturing and testing of FDCs, as well as the potential benefits of FDCs compared to two or three separate drug products. Dr. Qu’s presentation will include several case studies where FDCs were developed at Halo and used in adult and pediatric products, and scientific approaches to overcoming processing challenges associated with FDC development.
“Fixed-dose combination products offer several advantages for both pharmaceutical companies and their patients,” says Dr. Qu in a company press release. “For patients, this includes more convenient dosing for better compliance and associated improved clinical performance, as well as the potential for reduced side effects, and fewer copayments and prescription refills. For pharmaceutical companies, FDCs can improve patient compliance, lower production and testing costs, and, in some cases, offer additional intellectual property protection and market share.”
For more information, visit www.cphinorthamerica.com.
Source: Halo Pharma